Sanders, Asked About Abuse in 340B, Cites His Past Effort to End a Hospital’s Tax Exemption

Sen. Bernie Sanders speaking at a podium
Senate HELP chair Bernie Sanders (I-Vt.) talked about taking away hospitals' tax-exempt status when he was asked during an interview about alleged hospital abuse of 340B.

U.S. Sen. Bernie Sanders (I-Vt.), the new chair of the Senate committee that oversees the 340B program, recently answered a reporter’s question about alleged hospital abuse of 340B by noting that he tried to revoke a Burlington, Vt., hospital’s tax-exempt

Read More »

More Entities Might Share 340B Contract Pharmacy Claims Data if the Process Improves and Actually Restores 340B Pricing, Survey Shows

laptop screen depicting data upload
More 340B entities would share contract pharmacy claims data with manufacturers if the process was better and got 340B pricing turned back on reliably, a survey by McKesson found.

While most 340B covered entities do not share their contract pharmacy claims data with drug makers to restore access to 340B pricing, many would do so if the process was better and got 340B pricing turned back on reliably, a

Read More »
Industry Insights Logo

What’s the Secret to 340B and Specialty Pharmacy Provider and Patient Engagement?

SPONSORED CONTENT

The rise in digital technologies in the healthcare sector during the COVID-19 pandemic has resulted in some interesting trends in medical communication as we move closer to a post-pandemic world.

During the pandemic, patients became more engaged with medical communication than ever. They went from attending doctor’s visits in-person to

Read More »

Inspector General Advises CMS to Monitor Non-Hospital 340B Entities’ Use of Modifiers on Part B Drug Claims

OIG challenge and solution chart
HHS OIG says CMS should monitor non-hospital covered entities' use of 340B modifiers when submitting Part B claims.

The U.S. Department of Health and Human Services Office of the Inspector General says the Centers for Medicare and Medicaid Services should monitor non-hospital 340B covered entities’ use of modifiers to identify 340B-priced drugs in Part B claims, as these

Read More »

340B Stakeholders Weigh in on HRSA’s Proposal to Replace 340B Dispute Resolution Process

Screenshot of regulations.gov 340B drug pricing program ADR document details.
340B contract pharmacy loomed large in stakeholders’ comments on HRSA's proposed revamp of the 340B program’s administrative dispute resolution system.

The fight over 340B contract pharmacy loomed large in stakeholders’ comments last week on a proposed federal regulation to revamp the 340B program’s administrative dispute resolution system.

Health care provider groups, citing manufacturers’ contract pharmacy policies, said they want the

Read More »

340B Hospital Physician Affiliated with Free-Market Think Tank Says Abolishing 340B Should be on the Table in Health Affairs Essay

Dr. Anthony DiGiorgio headshot
“Consideration could be given to abolishing" the 340B program, Dr. Anthony DiGiorgio of Zuckerberg San Francisco General Hospital and Trauma Center writes in the policy journal Health Affairs. DiGiorgio says he receives funding from a free-market think tank "on Medicaid and access to care issues."

A neurosurgeon at a San Francisco 340B hospital who once was a health policy fellow for U.S. Sen. Bill Cassidy (R-La.) and who is doing research for a free-market oriented think tank has written a stinging reply to former U.S.

Read More »

Bernie Sanders Officially Named Chair and Bill Cassidy Ranking Republican of Senate HELP Panel

Sen. Bernie Sanders and Sen. Bill Cassidy headshots
Sen. Bernie Sanders (I-Vt.) (left), is the new chair of the Senate HELP Committee and Sen. Bill Cassidy (R-La.) is its new ranking Republican.

The U.S. Senate committee with jurisdiction over 340B is officially under new leadership, with Bernie Sanders (I-Vt.) being seated as Health, Education, Labor, and Pensions chair last week and Bill Cassidy (R-La.) as ranking Republican.

The formal announcements had been

Read More »

GSK Announces Refunds for 340B Overcharges on Respiratory Drugs

GSK GlaxoSmithKline logo on office building
GlaxoSmithKline said last week it would pay refunds for 340B overcharges occurring in Q1 2021.

Pharmaceutical manufacturer GlaxoSmithKline said last week it would pay refunds for 340B overcharges occurring in the first quarter of 2021, including overcharges for blockbuster respiratory drugs Trelegy and Nucala.

The refund notice posted Feb. 2 on the U.S. Health

Read More »

340B INDUSTRY LEADER SPOTLIGHT

Andrew Crawford, Senior Vice President, Business Development, Maxor National Pharmacy Services

Andrew Crawford headshot
Drew Crawford

Q: Where did you grow up?

In Macon, GA, primarily (that is where I graduated high school)

Q: Where did you go to college?

Washington and Lee University

Q: What are your favorites?

Food: Indian

Movie: The Shawshank Redemption or Star Wars, The Empire Strikes Back

Musicians: Pearl Jam, Led Zeppelin, Chris Singleton

Destination: Scotland 

Q:

Read More »

Drugmakers Urge Appeals Courts to Follow Third Circuit Ruling and Uphold 340B Contract Pharmacy Restrictions

Digital rendering of a courtroom
Lilly, Novartis, and United Therapeutics want the appeals courts hearing their 340B contract pharmacy cases to follow the lead of the appeals court in AstraZeneca, Sanofi, and Novo Nordisk’s cases and uphold their 340B policies.

Drugmakers Lilly, Novartis, and United Therapeutics this week urged federal appeals courts in Chicago and Washington, D.C., to follow the lead of the appeals court in Philadelphia and uphold their restrictions on 340B providers’ use of contract pharmacies.   

Lilly on

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live